The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A phase 1 dose-escalation study of RiMO-301 with palliative radiation in advanced tumors.
 
Matthew Koshy
No Relationships to Disclose
 
Michael Spiotto
No Relationships to Disclose
 
Lawrence Eric Feldman
Research Funding - E.R. Squibb Sons, LLC (Inst); Genentech (Inst); Roche (Inst)
 
Jason J. Luke
Stock and Other Ownership Interests - Actym Therapeutics; Alphamab; Arch Oncology; Kanaph Therapeutics; Mavu Pharmaceutical; NeoTX; NeoTX; Onc.AI; Pyxis; STipe Therapeutics; Tempest Therapeutics
Consulting or Advisory Role - 7 Hills Pharma; Abbvie; Alnylam; Alphamab; Bayer; Bright Peak Therapeutics; Bristol-Myers Squibb; Checkmate Pharmaceuticals; Codiak Biosciences; Crown Bioscience; CStone Pharmaceuticals; Day One Therapeutics; EMD Serono; Endeavor BioMedicines; Flame Biosciences; Genentech; Gilead Sciences; Hotspot Therapeutics; Immunocore; Incyte; Inzen Therapeutics; Janssen; Kadmon; KSQ Therapeutics; Merck; Nektar; Novartis; Onc.AI; Partner Therapeutics; Pfizer; Reflexion Medical; Regeneron; Ribon Therapeutics; Rubius Therapeutics; SERVIER; Silicon Therapeutics; STINGthera; STipe Therapeutics; Synlogic; Synthekine; Tempest Therapeutics; Tesaro; TRex Bio; Werewolf Therapeutics; Xencor; Xilio Therapeutics
Research Funding - Abbvie (Inst); Agios (Inst); Array BioPharma (Inst); Astellas Pharma (Inst); BioNTech (Inst); Bristol-Myers Squibb (Inst); Corvus Pharmaceuticals (Inst); EMD Serono (Inst); Fstar (Inst); Genmab (Inst); Ikena Oncology (Inst); Immatics (Inst); Incyte (Inst); Kadmon (Inst); KAHR Medical (Inst); Macrogenics (Inst); Merck (Inst); Moderna Therapeutics (Inst); Nektar (Inst); NextCure (Inst); Numab (Inst); Replimune (Inst); Rubius Therapeutics (Inst); Scholar Rock (Inst); Spring bank (Inst); Synlogic (Inst); Takeda (Inst); Tizona Therapeutics, Inc. (Inst); Trishula Therapeutics (Inst); Xencor (Inst)
Patents, Royalties, Other Intellectual Property - Serial #15/612,657 (Cancer Immunotherapy),; Serial #PCT/US18/36052 (Microbiome Biomarkers for Anti-PD-1/PD-L1 Responsiveness: Diagnostic, Prognostic and Therapeutic Uses Thereof)
Travel, Accommodations, Expenses - Array BioPharma; Bristol-Myers Squibb; EMD Serono; Janssen; Merck; Mersana; Novartis; Pyxis; Reflexion Medical; Xilio Therapeutics
 
Gini F. Fleming
Honoraria - Physicans' Education Resource
Research Funding - Abbvie (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); AstraZeneca (Inst); Celldex (Inst); Compugen (Inst); Compugen (Inst); Corcept Therapeutics (Inst); CytomX Therapeutics (Inst); GlaxoSmithKline (Inst); Incyte (Inst); Iovance Biotherapeutics (Inst); K-Group Beta (Inst); Merck (Inst); Molecular Templates (Inst); P{fizer (Inst); Pfizer (Inst); Plexxikon (Inst); Roche (Inst); Sermonix Pharmaceuticals (Inst); Syros Pharmaceuticals (Inst)
Other Relationship - AstraZeneca (Inst); Caris Life Sciences (Inst); DSI (Inst); Eisai (Inst); Merck (Inst)
(OPTIONAL) Uncompensated Relationships - Abbvie
 
Daniel Olson
Consulting or Advisory Role - Gerson Lehrman Group; Iovance Biotherapeutics; MJH Life Sciences; Novartis
 
John William Moroney
No Relationships to Disclose
 
Rita Nanda
Consulting or Advisory Role - AstraZeneca; BeyondSpring Pharmaceuticals; Cardinal Health; Fujifilm; GE Healthcare; Gilead Sciences; Infinity Pharmaceuticals; ITeos Therapeutics; Merck; OBI Pharma; OncoSec; Sanofi; Seagen
Research Funding - Arvinas (Inst); AstraZeneca (Inst); Celgene (Inst); Corcept Therapeutics (Inst); Genentech/Roche (Inst); Immunomedics (Inst); Merck (Inst); OBI Pharma (Inst); Odonate Therapeutics (Inst); OncoSec (Inst); Pfizer (Inst); Relay Therapeutics (Inst); Seagen (Inst); Sun Pharma (Inst); Taiho Oncology (Inst)
Other Relationship - G1 Therapeutics
 
Ari Rosenberg
Stock and Other Ownership Interests - Galectin Therapeutics; Privo Technologies
Consulting or Advisory Role - Astellas Pharma; Eisai; EMD Serono; Nanobiotix; Novartis; Vaccitech
Speakers' Bureau - Coherus Biosciences
Research Funding - Hookipa Biotech (Inst); Sysmex (Inst)
 
Alexander T. Pearson
Stock and Other Ownership Interests - Inovalon (I); Privo Technologies
Consulting or Advisory Role - Abbvie; Ayala Pharmaceuticals; Elevar Therapeutics; Prelude Therapeutics
Research Funding - Abbvie (Inst); Kura Oncology (Inst)
 
Aditya Juloori
Consulting or Advisory Role - AquaLung Therapeutics; General Electric; Isoray
Research Funding - AstraZeneca
 
Frank Weinberg
Consulting or Advisory Role - Jazz Pharmaceuticals; Regeneron
Speakers' Bureau - Amgen
 
Charles Ray
Patents, Royalties, Other Intellectual Property - Editorial stipend Thieme
Expert Testimony - Multiple legal firms over the past two years
 
Ron C. Gaba
Stock and Other Ownership Interests - Sus Clinicals Inc.
Honoraria - Guerbet
Consulting or Advisory Role - Sus Clinicals Inc.
Research Funding - Guerbet (Inst); Janssen Research & Development (Inst); NeoTherma Oncology (Inst); TriSalus Life Sciences (Inst)
Patents, Royalties, Other Intellectual Property - Modeling Oncology on Demand (MOOD); United States Provisional Patent Application No. 62/813,307 (Inst)
 
Paul J Chang
Consulting or Advisory Role - AIDOC; Bayer; Subtle Medical
Research Funding - Philips Healthcare
 
Linda A. Janisch
No Relationships to Disclose
 
Ze-Qi Xu
Employment - Coordination Pharmaceuticals
Stock and Other Ownership Interests - Coordination Pharmaceuticals
 
Wenbin Lin
Leadership - Coordination Pharmaceuticals
Stock and Other Ownership Interests - Coordination Pharmaceuticals
 
Ralph R. Weichselbaum
Stock and Other Ownership Interests - AquaLung Therapeutics; Boost Therapeutics; Coordination Pharmaceuticals; Cyntegron Therapeutics; Immvira; Magi Therapeutics; Oncosenescence; Reflexion Pharmaceuticals
Honoraria - Highlight Therapeutics; Shuttle Pharmaceuticals
Consulting or Advisory Role - Aettis; AquaLung Therapeutics; AstraZeneca; Coordination Pharmaceuticals; Genus Oncology; Highlight Therapeutics; Merck Serono; Nano proteagen; NkGen Biotech; Reflexion Pharmaceuticals; Sanofi; Shuttle Pharmaceuticals
Research Funding - Regeneron; Varian Medical Systems
Patents, Royalties, Other Intellectual Property - Boost Therapeutics; METHODS AND KITS FOR DIAGNOSIS AND TRIAGE OF PATIENTS WITH COLORECTAL LIVER METASTASES Publication number: 20210115519 Abstract: Methods, assays, and compositions for identifying molecular subtypes of metastatic cancer are disclosed. Methods include dete; Oncosenescence; Reflexion Pharmaceuticals; Tvec
 
Steven J. Chmura
Employment - Astellas Pharma (I); Takeda (I)
Honoraria - Reflexion Medical
Consulting or Advisory Role - AstraZeneca; Genentech
Research Funding - AstraZeneca/MedImmune; BMS; Merck
Patents, Royalties, Other Intellectual Property - UptoDate article